Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

213 ta ish

Ish: Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology

  1. The paths and challenges of “off-the-shelf” CAR-T cell therapy: An overview of clinical trials

    Vahid Moradi, Azadeh Omidkhoda, Naser Ahmadbeigi

    Sharh maqola20239 iqtibos
    ABI

  2. Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

    Vahid Moradi, Elnaz Khodabandehloo, Mehdi Alidadi +2

    Sharh maqola20248 iqtibos
    ABI

  3. Polymeric Nanoparticles for Drug Delivery

    Maximilian A. Beach, Umeka Nayanathara, Yanting Gao +4

    Sharh maqolaOchiq kirish20247 iqtibos
    ABI

  4. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

    Maqola20217 iqtibos
    ABI

  5. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner +32

    Maqola20187 iqtibos
    ABI

  6. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity

    Wenyan Fu, Changhai Lei, Shuowu Liu +12

    MaqolaOchiq kirish20195 iqtibos
    ABI

  7. Current hurdles to the translation of nanomedicines from bench to the clinic

    Snežana Đorđević, María Medel Gonzalez, Inmaculada Conejos‐Sánchez +6

    Sharh maqola20215 iqtibos
    ABI

  8. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

    Justin Eyquem, Jorge Mansilla‐Soto, Theodoros Giavridis +6

    MaqolaOchiq kirish20174 iqtibos
    ABI

  9. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth

    Pengxiang Yang, Xingjian Cao, Huilong Cai +7

    Maqola20204 iqtibos
    ABI

  10. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett +37

    Maqola20174 iqtibos
    ABI

  11. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Stephen J. Schuster, Michael Bishop, Constantine S. Tam +21

    Maqola20184 iqtibos
    ABI

  12. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani +33

    Maqola20214 iqtibos
    ABI

  13. Focusing on exosomes to overcome the existing bottlenecks of CAR-T cell therapy

    Siheng Zhang, Linglong Peng, Yifei Chen +2

    Sharh maqola20244 iqtibos
    ABI

  14. Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects

    Mehdi Alidadi, Haniyeh Barzgar, Mohammad Asif Zaman +4

    Sharh maqola20244 iqtibos
    ABI

  15. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

    Zhenguang Wang, Na Li, Kaichao Feng +14

    MaqolaOchiq kirish20213 iqtibos
    ABI

  16. Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering

    Ke Si, Zhu Dai, Zhanping Li +6

    Maqola20233 iqtibos
    ABI

  17. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

    Na Tang, Chen Cheng, Xingying Zhang +6

    Maqola20203 iqtibos
    ABI

  18. Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery

    Jialiang Wang, Yaopeng Ding, K. Chul Chong +7

    Sharh maqola20243 iqtibos
    ABI

  19. Sarlavhasiz

    Boshqa3 iqtibos
    ABI

  20. The paths toward non-viral CAR-T cell manufacturing: A comprehensive review of state-of-the-art methods

    Yekta Metanat, Patrik Viktor, Ayesha Amajd +10

    Sharh maqola20243 iqtibos
    ABI

  21. From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy

    Eleonora Pinto, Lisa A. Lione, Mirco Compagnone +8

    Sharh maqola20253 iqtibos
    ABI

  22. CD19.CAR T-cell–derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy

    Paola Lanuti, Francesco Guardalupi, Giulia Corradi +32

    Maqola20253 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa3 iqtibos
    ABI

  24. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype

    Darya Alizadeh, Robyn A. Wong, Xin Yang +11

    MaqolaOchiq kirish20192 iqtibos
    ABI

  25. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

    Maria‐Luisa Schubert, Michael Schmitt, L. Wang +4

    Sharh maqolaOchiq kirish20202 iqtibos
    ABI